alosetron has been researched along with Dyspepsia in 5 studies
alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.
Dyspepsia: Impaired digestion, especially after eating.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 320 functional dyspepsia patients received placebo (n=81), or alosetron 0." | 9.09 | A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. ( Dukes, G; Heath, M; Kleoudis, C; Mangel, AW; Perschy, T; Saez, LR; Talley, NJ; Van Zanten, SV, 2001) |
| "A total of 320 functional dyspepsia patients received placebo (n=81), or alosetron 0." | 5.09 | A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. ( Dukes, G; Heath, M; Kleoudis, C; Mangel, AW; Perschy, T; Saez, LR; Talley, NJ; Van Zanten, SV, 2001) |
| ", 2D6 and 2C19), and the effects of genetic polymorphisms in the promoter of the serotonin transporter protein, which influence the response to alosetron in patients with diarrhea-predominant irritable bowel syndrome." | 4.82 | Pharmacogenomics and functional gastrointestinal disorders. ( Camilleri, M, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dance, A | 1 |
| Camilleri, M | 3 |
| Coulie, B | 1 |
| Talley, NJ | 1 |
| Van Zanten, SV | 1 |
| Saez, LR | 1 |
| Dukes, G | 1 |
| Perschy, T | 1 |
| Heath, M | 1 |
| Kleoudis, C | 1 |
| Mangel, AW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Randomized, Investigator Blinded, Controlled Trial to Evaluate the Effectiveness of Dietary Modification in Patients With Functional Dyspepsia[NCT02863822] | 0 participants (Actual) | Interventional | 2016-09-30 | Withdrawn (stopped due to no patients enrolled) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for alosetron and Dyspepsia
| Article | Year |
|---|---|
Pharmacogenomics and functional gastrointestinal disorders.
Topics: Carbolines; Colonic Diseases, Functional; Diarrhea; Dyspepsia; Gastrointestinal Agents; Humans; Mode | 2005 |
Pharmacogenomics and serotonergic agents: research observations and potential clinical practice implications.
Topics: Appetite Depressants; Carbolines; Cyclobutanes; Dyspepsia; Gastrointestinal Agents; Genetic Variatio | 2007 |
New therapies for functional bowel diseases.
Topics: Carbolines; Colonic Diseases, Functional; Dyspepsia; Gastrointestinal Agents; Humans; Psychotherapy | 2000 |
1 trial available for alosetron and Dyspepsia
| Article | Year |
|---|---|
A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia.
Topics: Administration, Oral; Adult; Carbolines; Dose-Response Relationship, Drug; Double-Blind Method; Dysp | 2001 |
1 other study available for alosetron and Dyspepsia
| Article | Year |
|---|---|
Transit time.
Topics: Anti-Bacterial Agents; Biofeedback, Psychology; Carbolines; Colitis; Diet; Dysentery; Dyspepsia; Egy | 2016 |